Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate (ORR) of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.